Document Detail


Occurrence and impact of intracranial pressure elevation during treatment of severe intraventricular hemorrhage.
MedLine Citation:
PMID:  22430237     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Elevated intracranial pressure is one of the proposed mechanisms leading to poor outcomes in patients with intraventricular hemorrhage. We sought to characterize the occurrence and significance of intracranial hypertension in severe intraventricular hemorrhage requiring extraventricular drainage.
DESIGN: Prospective analysis from two randomized, multicenter, clinical trials.
SETTING: Intensive care units of 23 academic hospitals.
PATIENTS: One hundred patients with obstructive intraventricular hemorrhage and intracerebral hemorrhage volume <30 mL requiring emergency extraventricular drainage from two randomized multicenter studies comparing intraventricular recombinant tissue plasminogen activator (n=78) to placebo (n=22).
INTERVENTIONS: Intracranial pressure was recorded every 4 hrs in all patients and before and after a 1-hr extraventricular drainage closure period after injection. Intracranial pressure readings were analyzed at predefined thresholds and compared between treatment groups, before and after injection of study agent, and before and after opening of third and fourth ventricles on computed tomography. Impact on 30-day outcomes was assessed.
MEASUREMENTS AND MAIN RESULTS: Initial intracranial pressure ranged from -2 to 60 mm Hg (median; interquartile range, 11;10). Of 2576 intracranial pressure readings, 91.5% (2359) were ≤20 mm Hg, 1.6% were >30, 0.5% were >40, and 0.2% were >50 mm Hg. In a multivariate analysis, threshold events>20 mm Hg and >30 mm Hg were more frequent in placebo vs. recombinant tissue plasminogen activator-treated groups (p=.03 and p=.08, respectively). Intracranial pressure elevation>20 mm Hg occurred during a required 1-hr extraventricular drainage closure interval in 207 of 868 (23.8%) injections of study agent, although early reopening of the extraventricular drainage only occurred in 7.9%. After radiographic opening of the lower ventricular system, intracranial pressure events>20 mm Hg remained significantly associated with initial intraventricular hemorrhage volume (p=.002) and extraventricular drainage placement ipsilateral to the largest intraventricular hemorrhage volume (p=.001), but not with thrombolytic treatment (p=.05) or intracerebral hemorrhage volume (p=.14). Ventriculoperitoneal shunts were required in 13.6% of placebo and 6.4% of recombinant tissue plasminogen activator-treated patients (p=.37). Percentage of intracranial pressure readings per patient>30 mm Hg and initial intracerebral hemorrhage and intraventricular hemorrhage volumes were independent predictors of 30-day mortality after adjustment for other outcome predictors (p=.003, p=.03, and p<.001, respectively). Independent predictors of poor modified Rankin Scale score at 30 days were percent of intracranial pressure events>30 mm Hg per patient (p=.01; but not >20 mm Hg), both intracerebral hemorrhage and intraventricular hemorrhage volume, and pulse pressure.
CONCLUSIONS: Intracranial pressure is not frequently elevated during monitoring and drainage with an extraventricular drainage in patients with severe intraventricular hemorrhage, although intracranial pressure >30 mm Hg predicts higher short-term mortality. Thrombolytic therapy may reduce the frequency of high intracranial pressure events. Intracranial pressure elevation appears to be significantly correlated with extraventricular drainage placement in the ventricle with greatest clot volume.
Authors:
Wendy C Ziai; Eric Melnychuk; Carol B Thompson; Issam Awad; Karen Lane; Daniel F Hanley
Related Documents :
20422337 - Epidermal growth factor protects the heart against low-flow ischemia-induced injury.
18006447 - S-nitroso human serum albumin reduces ischaemia/reperfusion injury in the pig heart aft...
15828947 - Analysis of ischemia-reperfusion injury in a microcirculatory model of pressure ulcers.
10616087 - Comparative neuroprotective efficacy of prolonged moderate intraischemic and postischem...
21512817 - Effects of cpap on gastric pouch pressure after bariatric surgery.
25227337 - Pulmonary artery systolic pressure and mortality in the oldest old.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Critical care medicine     Volume:  40     ISSN:  1530-0293     ISO Abbreviation:  Crit. Care Med.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-19     Completed Date:  2012-06-11     Revised Date:  2012-12-14    
Medline Journal Info:
Nlm Unique ID:  0355501     Medline TA:  Crit Care Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1601-8     Citation Subset:  AIM; IM    
Affiliation:
Department of Neurology, Division of Neurocritical Care, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. weziai@jhmi.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Cerebral Hemorrhage / complications*,  drug therapy,  physiopathology
Drainage
Female
Humans
Intracranial Hypertension / etiology*,  surgery,  therapy
Intracranial Pressure / physiology
Male
Middle Aged
Monitoring, Physiologic
Recombinant Proteins / therapeutic use
Tissue Plasminogen Activator / therapeutic use
Ventriculoperitoneal Shunt
Grant Support
ID/Acronym/Agency:
1R01 NS 24282-08/NS/NINDS NIH HHS; FD-R-001693-01-1/FD/FDA HHS
Chemical
Reg. No./Substance:
0/Recombinant Proteins; EC 3.4.21.68/Tissue Plasminogen Activator
Comments/Corrections
Comment In:
Crit Care Med. 2012 May;40(5):1683-5   [PMID:  22511164 ]
Crit Care Med. 2012 Nov;40(11):3115-6; author reply 3116   [PMID:  23080469 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Angiopoietin-2 in acute liver failure.
Next Document:  Role of receptor for advanced glycation end products in cardiogenic shock.